EPCAM and cancer: In an autologous organoid/CTL co-culture derived from patients with PD-L1-positive tumors, organoids were sensitive to nivolumab treatment (condition 2), whereby the addition of PMN-MDSCs inhibited nivolumab-induced EpCAM+ cancer organoid death (condition 4, Figure 7F).